## WHAT IS CLAIMED IS:

1. A compound represented by Formula (I) or (II):

$$\begin{array}{c|c}
R^7 & R^4 & N \\
R^6 & N \\
R^5 & N \\
R^2 & R^2
\end{array}$$
(I)

5

$$\begin{array}{c|c}
R_7 & R_4 & N \\
R_6 & R_5 & R_2 & N & N
\end{array}$$

**(II)** 

or a pharmaceutically acceptable salt thereof, wherein

 $10 R^{1}$  is

(a) H,

(b)  $C_1$ - $C_6$ -alkyl,  $C_2$ - $C_4$ -alkenyl,  $C_2$ - $C_4$ -alkynyl, any of which is optionally substituted with one or more of the following substituents:  $NR^aR^b$ , COOH,  $CONR^aR^b$ , or

(c) -C(=O)R<sup>a</sup>, COOR<sup>a</sup>, CONR<sup>a</sup>R<sup>b</sup>;

15

Ra is:

(a) H,

- (b) C<sub>1</sub>-C<sub>6</sub>-alkyl, optionally substituted with one or more of halogen or CF<sub>3</sub> or
- (c) CF<sub>3</sub>;

20

R<sup>b</sup> is

- (a) H, or
- (b) C<sub>1</sub>-C<sub>6</sub>-alkyl, optionally substituted with one or more of halogen or CF<sub>3</sub>, or
- (c) CF<sub>3</sub>;
- 5  $R^2$  is H or  $C_{1-4}$  alkyl;

R<sup>3</sup> and R<sup>4</sup> each independently is:

- (a) H,
- (b)  $-C_0-C_4$ -alkyl- $C_1-C_4$ -perfluoroalkyl or  $-O-C_0-C_4$ -alkyl- $C_1-C_4$ -perfluoroalkyl,
- 10 (c) halogen, or
  - (d) -C<sub>1</sub>-C<sub>6</sub> alkyl, optionally substituted with one or more of halogen or CF<sub>3</sub>; and

R<sup>5</sup>, R<sup>6</sup> and R<sup>7</sup> each independently is:

- (a) H,
- (b) -O- C<sub>1</sub>-C<sub>6</sub>-alkyl, -O- C<sub>1</sub>-C<sub>6</sub>-alkenyl, -O- C<sub>1</sub>-C<sub>6</sub>-alkynyl, any of which is optionally substituted with one or more of halogen or CF<sub>3</sub>,
  - (c)  $-C_0-C_4$ -alkyl- $C_1-C_4$ -perfluoroalkyl, or  $-O-C_0-C_4$ -alkyl- $C_1-C_4$ -perfluoroalkyl,
  - (d) -O-phenyl, or -O-C<sub>1</sub>-C<sub>4</sub>-alkyl-phenyl, wherein phenyl is optionally substituted with 1-3 substituents selected from i) halogen, ii) -CN, iii) -NO<sub>2</sub>, iv) CF<sub>3</sub>, v) -OR<sup>a</sup>, vi) -NR<sup>a</sup>R<sup>b</sup>, vii) -C<sub>0</sub>-
- 4alkyl-CO-OR<sup>a</sup>, viii) -(C<sub>0-4</sub>alkyl)-CO-N(R<sup>a</sup>)(R<sup>b</sup>), ix) and x) -C<sub>1-10</sub> alkyl, wherein one or more of the alkyl carbons can be replaced by a –NR<sup>a</sup>, C(O)-O-, or -N(R<sup>a</sup>)-C(O)-N(R<sup>a</sup>)-, or
  - (e) halogen,  $-OR^a$ , or phenyl wherein phenyl is optionally substituted with 1-3 substituents selected from i) halogen, ii) -CN, iii)  $-NO_2$ , iv)  $CF_3$ , v) pyrazolyl, vi)  $-OR^a$ , vii)  $-NR^aR^b$ , viii)  $-C_0$ -4alkyl-CO-OR, ix)  $-(C_0$ -4alkyl)-CO-N( $R^a$ )( $R^b$ ), and x)  $-C_{1-10}$ alkyl, wherein one or more of
- 25 the alkyl carbons can be replaced by a  $-NR^a$ , C(O)-O-, or  $-N(R^a)-C(O)-N(R^a)-$ .
  - 2. The compound of Claim 1 described by the chemical Formula (I), or a pharmaceutically acceptable salt thereof, wherein

R<sup>5</sup> is other than H and is attached at the ortho position.

|    | wherein   | 3.  | The compound of Claim 2, or a pharmaceutically acceptable salt thereof,                                      |
|----|-----------|-----|--|
|    | wherem    |     | R <sup>5</sup> is optionally substituted -O- C <sub>1</sub> -C <sub>6</sub> -alkyl.                          |
| 5  | wherein   | 4.  | The compound of Claim 2, or a pharmaceutically acceptable salt thereof,                                      |
|    |           |     | R <sup>5</sup> is optionally substituted phenyl.   |
|    |           | 5.  | The compound of Claim 2, or a pharmaceutically acceptable salt thereof,                                      |
| 10 | wherein   |     | R <sup>5</sup> is -O-C <sub>1</sub> -C <sub>4</sub> -alkyl-phenyl, wherein phenyl is optionally substituted. |
| 15 | wherein   | 6.  | The compound of Claim 2, or a pharmaceutically acceptable salt thereof,                                      |
|    |           |     | R <sup>5</sup> is optionally substituted –O-C <sub>1</sub> -C <sub>6</sub> -alkenyl.                         |
|    | wherein   | 7.  | The compound of Claim 2, or a pharmaceutically acceptable salt thereof,                                      |
|    |           |     | R <sup>6</sup> is halogen.   |
| 20 | wherein   | 8.  | The compound of Claim 2, or a pharmaceutically acceptable salt thereof,                                      |
|    | WIICICIII |     | R <sup>3</sup> is halogen.   |
| 25 | wherein   | 9.  | The compound of Claim 2, or a pharmaceutically acceptable salt thereof,                                      |
|    |           |     | R <sup>3</sup> and R <sup>4</sup> are halogen.   |
|    | wherein   | 10. | The compound of Claim 2, or a pharmaceutically acceptable salt thereof                                       |

R<sup>3</sup>, R<sup>4</sup> and R<sup>6</sup> are halogen.

11. The compound of Claim 2, or a pharmaceutically acceptable salt thereof, wherein

 $R^3$  is  $-O-C_0-C_4$ -alkyl- $C_1-C_4$ -perfluoroalkyl.

5

20

25

wherein

12. The compound of Claim 1 described by the chemical Formula (II), or a pharmaceutically acceptable salt thereof, wherein

R<sup>5</sup> is other than H and is attached at the ortho position.

1013. The compound of Claim 12, or a pharmaceutically acceptable salt thereof,

R<sup>5</sup> is optionally substituted -O- C<sub>1</sub>-C<sub>6</sub>-alkyl.

- 15 The compound of Claim 12, or a pharmaceutically acceptable salt thereof, wherein R<sup>5</sup> is optionally substituted phenyl.
  - 15. The compound of Claim 12, or a pharmaceutically acceptable salt thereof, wherein

 $R^5$  is  $-O-C_1-C_4$ -alkyl-phenyl, wherein phenyl is optionally substituted.

The compound of Claim 12, or a pharmaceutically acceptable salt thereof, wherein  $R^5 \ \text{is optionally substituted } -O-C_1-C_6\text{-alkenyl}.$ 

The compound of Claim 12, or a pharmaceutically acceptable salt thereof, wherein  $R^3 \ \text{is halogen}. \label{eq:R3}$ 

- The compound of Claim 12, or a pharmaceutically acceptable salt thereof, wherein  $R^3 \ \text{and} \ R^4 \ \text{are halogen}.$
- 20. The compound of Claim 12, or a pharmaceutically acceptable salt thereof, wherein  $R^{3}, R^{4} \ \text{and} \ R^{6} \ \text{are halogen}.$
- The compound of Claim 12, or a pharmaceutically acceptable salt thereof, wherein

  R<sup>3</sup> is -O-C<sub>0</sub>-C<sub>4</sub>-alkyl-C<sub>1</sub>-C<sub>4</sub>-perfluoroalkyl.
  - 22. A compound represented by Formula (III)

$$R_7$$
 $R_6$ 
 $R_4$ 
 $R_5$ 
 $R_4$ 
 $R_7$ 
 $R_1$ 
 $R_1$ 
 $R_1$ 
 $R_2$ 
 $R_1$ 

- 20 or a pharmaceutically acceptable salt thereof, wherein  $R^1 R^7$  each is as defined in Claim 1.
  - The compound of Claim 22, or a pharmaceutically acceptable salt thereof, whereinR<sup>5</sup> is other than H and is attached at the ortho position.

|    |           | 24. | The compound of Claim 23, or a pharmaceutically acceptable salt thereof,                                     |
|----|-----------|-----|--|
| 5  | wherein   |     | R <sup>5</sup> is optionally substituted -O- C <sub>1</sub> -C <sub>6</sub> -alkyl.                          |
|    | wherein   | 25. | The compound of Claim 23, or a pharmaceutically acceptable salt thereof,                                     |
|    |           |     | R <sup>5</sup> is optionally substituted phenyl.   |
|    |           | 26. | The compound of Claim 23, or a pharmaceutically acceptable salt thereof,                                     |
| 10 | wherein   |     | R <sup>5</sup> is -O-C <sub>1</sub> -C <sub>4</sub> -alkyl-phenyl, wherein phenyl is optionally substituted. |
| 15 | wherein   | 27. | The compound of Claim 23, or a pharmaceutically acceptable salt thereof,                                     |
|    | Wilcioni  |     | R <sup>5</sup> is optionally substituted -O-C <sub>1</sub> -C <sub>6</sub> -alkenyl.                         |
|    | wherein   | 28. | The compound of Claim 23, or a pharmaceutically acceptable salt thereof,                                     |
|    | W11010111 |     | R <sup>6</sup> is halogen.   |
| 20 | wherein   | 29. | The compound of Claim 23, or a pharmaceutically acceptable salt thereof,                                     |
|    |           |     | R <sup>3</sup> is halogen.   |
| 25 | wherein   | 30. | The compound of Claim 23, or a pharmaceutically acceptable salt thereof,                                     |
|    |           |     | R <sup>3</sup> and R <sup>4</sup> are halogen.   |

31. The compound of Claim 23, or a pharmaceutically acceptable salt thereof, wherein  $R^{3}, R^{4} \mbox{ and } R^{6} \mbox{ are halogen}.$ 

5 32. The compound of Claim 23, or a pharmaceutically acceptable salt thereof, wherein  $R^3 \text{ is } -O\text{-}C_0\text{-}C_4\text{-alkyl-}C_1\text{-}C_4\text{-perfluoroalkyl}.$ 

33. A compound represented by

| N CONH <sub>2</sub>   | N CONH <sub>2</sub>  |
|---|--|
| CF <sub>3</sub> CF <sub>2</sub> CF <sub>2</sub> CH <sub>2</sub> O N CO <sub>2</sub> H   | N CONH <sub>2</sub>  |
| N-NH<br>N-NH<br>F   | N CONH <sub>2</sub>  |
| CH <sub>3</sub> CH <sub>2</sub> CH <sub>2</sub> CH <sub>2</sub> O F N CO <sub>2</sub> H | CF <sub>3</sub> CF <sub>2</sub> CH <sub>2</sub> O  N  N  CO <sub>2</sub> H |
| CF <sub>3</sub> CF <sub>2</sub> CH <sub>2</sub> O  N N N H CO <sub>2</sub> H            | N-N-CONH <sub>2</sub>  |
| CF <sub>3</sub> CF <sub>2</sub> CH <sub>2</sub> O F N-N CONH <sub>2</sub>               | CF <sub>3</sub> CF <sub>2</sub> CH <sub>2</sub> O  N  N  CONH <sub>2</sub> |

|   | ,   |
|---|---|
| CF <sub>3</sub> CF <sub>2</sub> CH <sub>2</sub> O N-N CONH <sub>2</sub> | N-N-CONH <sub>2</sub>   |
| CH <sub>3</sub> CH <sub>2</sub> CH <sub>2</sub> O N CONH <sub>2</sub>   | CH <sub>3</sub> CH <sub>2</sub> CH <sub>2</sub> O F N CONH <sub>2</sub> |
| CH <sub>2</sub> =CHCH <sub>2</sub> O N CONH <sub>2</sub>                | CH <sub>2</sub> =CHCH <sub>2</sub> O F N CONH <sub>2</sub>              |
| CF <sub>3</sub> CF <sub>2</sub> CH <sub>2</sub> O F N CONH <sub>2</sub> | CF <sub>3</sub> CF <sub>2</sub> CH <sub>2</sub> O F N CONH <sub>2</sub> |
| CF <sub>3</sub> O F N CONH <sub>2</sub>                                 | CF <sub>3</sub> CF <sub>2</sub> CH <sub>2</sub> O                       |
| CF <sub>3</sub> CF <sub>2</sub> CH <sub>2</sub> O N CONH <sub>2</sub>   | CF <sub>3</sub> CF <sub>2</sub> CH <sub>2</sub> O  N  N  N  N  H        |
| CF <sub>3</sub> O F N CONH <sub>2</sub>                                 | CF <sub>3</sub> CF <sub>3</sub> O<br>NN<br>NCONH <sub>2</sub>           |

| CF <sub>3</sub> O F N CONH <sub>2</sub> | CH <sub>3</sub> CH <sub>2</sub> O F N CONH <sub>2</sub>                        |
|---|--|
| CF <sub>3</sub> O N CONH <sub>2</sub>   | CF <sub>3</sub> CF <sub>2</sub> CH <sub>2</sub> O  N N N N H CONH <sub>2</sub> |
| F N CONH <sub>2</sub>                   | F F P CONH <sub>2</sub>  |
| F CONH <sub>2</sub>                     | F N CONH <sub>2</sub>  |
| F N CONH <sub>2</sub>                   | N-N-CONH <sub>2</sub>  |
| N-N-CONH <sub>2</sub> CF <sub>3</sub>   | N-N-CONH <sub>2</sub> CO <sub>2</sub> CH <sub>3</sub>                          |
| N $N$ $N$ $N$ $N$ $N$ $N$ $N$ $N$ $N$   | N CONH <sub>2</sub> OCF <sub>3</sub>   |

| CF <sub>3</sub> CF <sub>2</sub> CF <sub>2</sub> CH <sub>2</sub> O  N N N N H CONH <sub>2</sub> |   |
|--|---|
| N-N-N-CONH <sub>2</sub> OCF <sub>3</sub>   | CF <sub>3</sub> O CONH <sub>2</sub>     |
| N CONH <sub>2</sub> CF <sub>3</sub>  | N-N-N-CONH <sub>2</sub> CF <sub>3</sub> |
| N-N-CONH₂<br>CF <sub>3</sub>   | F N CONH <sub>2</sub>                   |
| F N N CONH <sub>2</sub>  | F CONH <sub>2</sub>                     |
| F CONH <sub>2</sub>  | F CONH <sub>2</sub>                     |

| N-N-N-CONH <sub>2</sub>                             | F<br>N-N<br>N-N<br>H CONH₂  |
|---|---|
| N CONH <sub>2</sub>                                 | F N CONH <sub>2</sub>   |
| $(CH_3)_2N$ $N$ $N$ $N$ $N$ $N$ $N$ $N$ $N$ $N$     | (CH <sub>3</sub> ) <sub>2</sub> N  N  N  N  N  N  N  N  N  N  N  N  N                       |
| NC<br>N-N-CONH <sub>2</sub>                         | N-N-CONH <sub>2</sub>   |
| N-N<br>N-N<br>H<br>N(CH <sub>3</sub> ) <sub>2</sub> | N-N-CONH <sub>2</sub> OCF <sub>3</sub>  |
| N_N CONH <sub>2</sub>                               | CF <sub>3</sub> CF <sub>2</sub> CF <sub>2</sub> CH <sub>2</sub> O F N CONH <sub>2</sub> N H |

5

- 34. A pharmaceutical composition comprising a therapeutically effective amount of a compound according to Claim 1, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier.
- 35. The pharmaceutical composition according to Claim 34, further comprising a second therapeutic agent selected from the group consisting of: i) opiate agonists, ii) opiate antagonists, iii) calcium channel antagonists, iv) 5HT receptor agonists, v) 5HT receptor antagonists vi) sodium channel antagonists, vii) NMDA receptor agonists, viii) NMDA receptor antagonists, ix) COX-2 selective inhibitors, x) NK1 antagonists, xi) non-steroidal anti-inflammatory drugs, xii) selective serotonin reuptake inhibitors, xiii) selective serotonin and norepinephrine reuptake inhibitors, xiv) tricyclic antidepressant drugs, xv) norepinephrine modulators, xvi) lithium, xvii) valproate, and xviii) neurontin.
- 36. A method of treatment or prevention of pain comprising the step of administering to a patient in need thereof a therapeutically effective amount, or a prophylactically effective amount, of a compound according to Claim 1, or a pharmaceutically acceptable salt thereof.
- 20 37. A method of treatment or prevention of chronic, visceral, inflammatory and/or neuropathic pain syndromes comprising the step of administering to a patient in need thereof a therapeutically effective amount, or a prophylactically effective amount, of a compound according to Claim 1, or a pharmaceutically acceptable salt thereof.
- 25 38. A method of treatment or prevention of pain resulting from, or associated with, traumatic nerve injury, nerve compression or entrapment, postherpetic neuralgia, trigeminal neuralgia, diabetic neuropathy, cancer and/or chemotherapy, comprising the step of administering

to a patient in need thereof a therapeutically effective amount, or a prophylactically effective amount, of a compound according to Claim 1, or a pharmaceutically acceptable salt thereof.

39. A method of treatment or prevention of chronic lower back pain comprising the step of administering to a patient in need thereof a therapeutically effective amount, or a prophylactically effective amount, of a compound according to Claim 1, or a pharmaceutically acceptable salt thereof.

- 40. A method of treatment or prevention of phantom limb pain comprising the step of administering to a patient in need thereof a therapeutically effective amount, or a prophylactically effective amount, of a compound according to Claim 1, or a pharmaceutically acceptable salt thereof.
- 41. A method of treatment or prevention of HIV- and HIV treatment-induced neuropathy, chronic pelvic pain, neuroma pain, complex regional pain syndrome, chronic arthritic pain and/or related neuralgias comprising the step of administering to a patient in need thereof a therapeutically effective amount, or a prophylactically effective amount, of a compound according to Claim 1, or a pharmaceutically acceptable salt thereof.
- 42. A method of administering local anesthesia comprising the step of administering to a patient in need thereof a therapeutically effective amount, or a prophylactically effective amount, of a compound according to Claim 1, or a pharmaceutically acceptable salt thereof.
- 43. A method of treatment or prevention of irritable bowel syndrome and/or Crohn's disease comprising the step of administering to a patient in need thereof a therapeutically effective amount, or a prophylactically effective amount, of a compound according to Claim 1, or a pharmaceutically acceptable salt thereof.
- 30 44. A method of treatment or prevention of epilepsy and/or partial and generalized tonic seizures comprising the step of administering to a patient in need thereof a

therapeutically effective amount, or a prophylactically effective amount, of a compound according to Claim 1, or a pharmaceutically acceptable salt thereof.

- 45. A method for neuroprotection under ischaemic conditions caused by stroke or neural trauma comprising the step of administering to a patient in need thereof a therapeutically effective amount, or a prophylactically effective amount, of a compound according to Claim 1, or a pharmaceutically acceptable salt thereof.
- 46. A method of treatment or prevention of multiple sclerosis comprising the step of administering to a patient in need thereof a therapeutically effective amount, or a prophylactically effective amount, of a compound according to Claim 1, or a pharmaceutically acceptable salt thereof.
- 47. A method of treatment or prevention of bipolar disorder comprising the step of administering to a patient in need thereof a therapeutically effective amount, or a prophylactically effective amount, of a compound according to Claim 1, or a pharmaceutically acceptable salt thereof.
- 48. A method of treatment or prevention of tachy-arrhythmias comprising the step of administering to a patient in need thereof a therapeutically effective amount, or a prophylactically effective amount, of a compound according to Claim 1, or a pharmaceutically acceptable salt thereof.
- 49. A method of treatment or prevention of migraine, headache pain and/or migraine headache comprising the step of administering to a patient in need thereof a therapeutically effective amount, or a prophylactically effective amount, of a compound according to Claim 1, or a pharmaceutically acceptable salt thereof.
- 50. A pharmaceutical composition comprising a therapeutically effective
  amount of a compound according to Claim 22, or a pharmaceutically acceptable salt thereof, and
  a pharmaceutically acceptable carrier.

51. The pharmaceutical composition according to Claim 49, further comprising a second therapeutic agent selected from the group consisting of: i) opiate agonists, ii) opiate antagonists, iii) calcium channel antagonists, iv) 5HT receptor agonists, v) 5HT receptor antagonists vi) sodium channel antagonists, vii) NMDA receptor agonists, viii) NMDA receptor antagonists, ix) COX-2 selective inhibitors, x) NK1 antagonists, xi) non-steroidal anti-inflammatory drugs, xii) selective serotonin reuptake inhibitors, xiii) selective serotonin and norepinephrine reuptake inhibitors, xiv) tricyclic antidepressant drugs, xv) norepinephrine modulators, xvi) lithium, xvii) valproate, and xviii) neurontin.

10

5

52. A method of treatment or prevention of pain comprising the step of administering to a patient in need thereof a therapeutically effective amount, or a prophylactically effective amount, of a compound according to Claim 22, or a pharmaceutically acceptable salt thereof.

15

53. A method of treatment or prevention of chronic, visceral, inflammatory and/or neuropathic pain syndromes comprising the step of administering to a patient in need thereof a therapeutically effective amount, or a prophylactically effective amount, of a compound according to Claim 22, or a pharmaceutically acceptable salt thereof.

20

25

- 54. A method of treatment or prevention of pain resulting from traumatic nerve injury, nerve compression or entrapment, postherpetic neuralgia, trigeminal neuralgia, diabetic neuropathy, cancer and/or chemotherapy comprising the step of administering to a patient in need thereof a therapeutically effective amount, or a prophylactically effective amount, of a compound according to Claim 22, or a pharmaceutically acceptable salt thereof.
- 55. A method of treatment or prevention of chronic lower back pain comprising the step of administering to a patient in need thereof a therapeutically effective amount, or a prophylactically effective amount, of a compound according to Claim 22, or a pharmaceutically acceptable salt thereof.

56. A method of treatment or prevention of phantom limb pain comprising the step of administering to a patient in need thereof a therapeutically effective amount, or a prophylactically effective amount, of a compound according to Claim 22, or a pharmaceutically acceptable salt thereof.

5

10

15

20

25

- 57. A method of treatment or prevention of HIV- and HIV treatment-induced neuropathy, chronic pelvic pain, neuroma pain, complex regional pain syndrome, chronic arthritic pain and/or related neuralgias comprising the step of administering to a patient in need thereof a therapeutically effective amount, or a prophylactically effective amount, of a compound according to Claim 22, or a pharmaceutically acceptable salt thereof.
- 58. A method of administering local anesthesia comprising the step of administering to a patient in need thereof a therapeutically effective amount, or a prophylactically effective amount, of a compound according to Claim 22, or a pharmaceutically acceptable salt thereof.
- 59. A method of treatment or prevention of irritable bowel syndrome and/or Crohn's disease comprising the step of administering to a patient in need thereof a therapeutically effective amount, or a prophylactically effective amount, of a compound according to Claim 22, or a pharmaceutically acceptable salt thereof.
- 60. A method of treatment or prevention of epilepsy and/or partial and generalized tonic seizures comprising the step of administering to a patient in need thereof a therapeutically effective amount, or a prophylactically effective amount, of a compound according to Claim 22, or a pharmaceutically acceptable salt thereof.
- 61. A method for neuroprotection under ischaemic conditions caused by stroke or neural trauma comprising the step of administering to a patient in need thereof a therapeutically effective amount, or a prophylactically effective amount, of a compound according to Claim 22, or a pharmaceutically acceptable salt thereof.

62. A method of treatment or prevention of multiple sclerosis comprising the step of administering to a patient in need thereof a therapeutically effective amount, or a prophylactically effective amount, of a compound according to Claim 22, or a pharmaceutically acceptable salt thereof.

5

63. A method of treatment or prevention of bipolar disorder comprising the step of administering to a patient in need thereof a therapeutically effective amount, or a prophylactically effective amount, of a compound according to Claim 22, or a pharmaceutically acceptable salt thereof.

10

64. A method of treatment or prevention of tachy-arrhythmias comprising the step of administering to a patient in need thereof a therapeutically effective amount, or a prophylactically effective amount, of a compound according to Claim 22, or a pharmaceutically acceptable salt thereof.

15

65. A method of treatment or prevention of migraine, headache pain and/or migraine headache comprising the step of administering to a patient in need thereof a therapeutically effective amount, or a prophylactically effective amount, of a compound according to Claim 22, or a pharmaceutically acceptable salt thereof.